TTR and Alzheimer disease: The levels of endogenous CTS in blood are altered in neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (Orellana et al., 2016; Lopachev et al., 2018; Fedorova et al., 2020).